This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Study design
This was a randomised, non-blinded study carried out at two hospitals. The patients were assigned to one of the two groups using sealed envelopes. The duration of the study was 12 weeks. Thirteen patients (13%) withdrew before the end of the 12 weeks, including 5 in the control (IFN) group and 8 in the intervention (IFN+VBL) group. The control group patients all withdrew due to severe toxicity. The reasons for withdrawal were more varied among the intervention group. Two refused to continue, 2 suffered progression in their bone metastases, 1 had severe toxicity, 1 suffered a nonfatal myocardial infarction and 2 died.
Analysis of effectiveness
The data were analysed on an intention to treat basis. The authors reported "no obvious clinically important differences between the two treatment groups at baseline". The primary effectiveness outcomes were: the rates of complete response ("disappearance of all tumour markers and clinically measurable disease"), partial response ("50%-100% decrease in the sum of the products of the two longest perpendicular diameters of measurable lesions"), and stable disease ("<50% decrease or <25% increase in ... parameters").
The incidence of various treatment-related adverse events was also measured.
Effectiveness results
There were no statistically significant differences in the response rates or estimated survival between the two groups. Forty-two per cent of the IFN monotherapy patients versus 34% of the IFN+VBL patients had either complete response, partial response or stable disease.
More IFN+VBL patients (52%) experienced leukopenia than IFN monotherapy patients (24%), (p=0.013).
More IFN patients suffered severe fatigue (53%) than IFN+VBL patients (17%), (p=0.0008).
More IFN patients had greater than 10% weight loss (58%) than IFN+VBL patients (24%), (p=0.002).
The mean duration of fever was also greater among IFN patients.
The other toxicity results were not statistically significant.
Clinical conclusions
Combined treatment with IFN+VBL was better tolerated than IFN monotherapy, with no statistically significant decrease in the short-term effectiveness.
Measure of benefits used in the economic analysis
No summary health benefit measure was used. This was therefore a cost-consequences study.
Direct costs
The hospital costs included in the analysis were the IFN and VBL treatments and associated hospital stays, and other drugs including antibiotics. The resource use data were presumably collected alongside the trial between 1988 and 1993 inclusive. The quantities of IFN, VBL and hospital days were reported separately. No sources or dates were reported for the unit costs. Discounting was irrelevant as the costs referred to the 12-week treatment period only.
